Pitfalls associated with commonly used methods for pharmacoeconomic analyses

Pharmacotherapy

Volumn 22, Issue 2 II, 2002, Pages

  Klepser, Donald G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; HEALTH CARE COST; HOSPITALIZATION; METHODOLOGY; PHARMACOECONOMICS; PRACTICE GUIDELINE; RESEARCH; REVIEW;

EID: 0036153857     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.4.35s.33657     Document Type: Review

References (31)

1. Establishing value through pharmacoeconomics: The emerging third objective in clinical trials
2. Using pharmacoeconomic analysis to make drug insurance coverage decisions
3. Using economic evaluations to make formulary coverage decisions: So much for guidelines
4. The power of pharmacoeconomics
5. The role of pharmacoeconomic evaluations in disease management
6. Managed care guidelines for the economic evaluation of pharmaceuticals
7. Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics
8. Problems with the interpretation of pharmacoeconomic analyses: A review of submissions to the Australian pharmaceutical benefits scheme
9. Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals
10. Canadian guidelines for economic evaluation of pharmaceuticals: Canadian collaborative workshop for pharmacoeconomics
11. Evaluation of pharmacoeconomic studies: Utilization of a checklist
12. Pharmacoeconomic evaluation: Good clinical practices and methodology
13. The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals
14. A case for the adoption of pharmacoeconomic guidelines in Japan
15. Guidelines for pharmacoeconomic studies: The ways forward
16. The emerging government requirement for economic evaluation of pharmaceuticals
17. The Danish approach to standards for economic evaluation methodologies
18. The journal's policy on cost-effectiveness analyses
19. Emerging standardization in pharmacoeconomics
20. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis
21. Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy
22. Oral ciprofloxacin: A pharmacoeconomic evaluation of its use in the treatment of serious infections
23. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia
24. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime
25. A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals
26. Cost analysis of imipenem-cilastatin versus clindamycin with tobramycin in the treatment of acute intra-abdominal infection
27. Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections
28. Are pharmacoeconomic studies pertinent?
29. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team
30. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
31. Pharmacoeconomic evaluation in the real world: Effectiveness versus efficacy studies